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Background: Obesity is an increasingly prevalent metabolic disorder in the modern
world and is associated with structural and functional changes in the heart. The
NLRP3 inflammasome is an innate immune sensor that can be activated in response
to endogenous danger signals and triggers activation of interleukin (IL)-1β and
IL-18. Increasing evidence points to the involvement of the NLRP3 inflammasome in
obesity-induced inflammation and insulin resistance, and we hypothesized that it also
could play a role in the development of obesity induced cardiac alterations.
Methods and Results: WT, Nlrp3−/−, and ASC−/− (Pycard−/−) male mice were
exposed to high fat diet (HFD; 60 cal% fat) or control diet for 52 weeks. Cardiac
structure and function were evaluated by echocardiography and magnetic resonance
imaging, respectively. Whereas, NLRP3 and ASC deficiency did not affect the cardiac
hypertrophic response to obesity, it was preventive against left ventricle concentric
remodeling and impairment of diastolic function. Furthermore, whereas NLRP3 and
ASC deficiency attenuated systemic inflammation in HFD fed mice; long-term HFD did
not induce significant cardiac fibrosis or inflammation, suggesting that the beneficial
effects of NLRP3 inflammasome deficiency on myocardial remodeling at least partly
reflect systemic mechanisms.Nlrp3 and ASC (Pycard) deficient mice were also protected
against obesity-induced systemic metabolic dysregulation, as well as lipid accumulation
and impaired insulin signaling in hepatic and cardiac tissues.
Conclusions: Our data indicate that the NLRP3 inflammasome modulates cardiac
concentric remodeling in obesity through effects on systemic inflammation and
metabolic disturbances, with effect on insulin signaling as a potential mediator within
the myocardium.
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INTRODUCTION
Obesity is an emerging health problem in the modern world,
leading to a reduced life expectancy, and is defined as
increased adipose mass resulting from a chronic imbalance
between energy intake and expenditure (1). Obesity-related
conditions, such as insulin resistance, type 2 diabetes
mellitus (T2DM), cardiovascular disorders (CVD), non-
alcoholic fatty liver disease (NAFLD) are a great concern,
in particular in developing countries, but the mechanisms
by which obesity promotes these disorders still remains
unclear (2, 3).
Abundant evidence suggests that obesity is accompanied
by structural and functional alterations in the heart (4–6).
According to a recently established paradigm regarding the
impact of obesity on the cardiac geometry, obesity is associated
with left ventricle (LV) hypertrophy with predominance of
concentric remodeling (4–6). The majority of published studies
have concluded that obesity results in subclinical impairment
of LV systolic and diastolic functions, which are believed to
be precursors to more overt forms of cardiac dysfunction and
heart failure (HF). Several theories have been postulated to
explain these obesity-associated cardiac abnormalities, such as
alterations in myocardial substrate utilization, mitochondrial
dysfunction, neurohormonal dysfunction, leptin resistance, and
impaired insulin signaling (4, 7–10). However, the multifaceted
interplay between direct cardiac effects of obesity and its
associated comorbidities (i.e., T2DM and atherosclerosis)
that also impact the myocardium makes it challenging to
understand the relation between obesity and different aspects of
cardiac remodeling.
The cytosolic pattern recognition receptor NLRP3 is an
important part of the innate immune system that can sense
danger signals from various microbes, as well as non-microbial
endogenous signals, such as extracellular ATP, crystals, saturated
fatty acids (FA) and certain other metabolic stress-related
molecules (11–14). Upon activation, that occurs in a two-
step manner, NLRP3 forms a multiprotein complex called
NLRP3 inflammasome with the adaptor protein ASC, also
referred to as Pycard, resulting in caspase-1 activation. Active
caspase-1 cleaves the pro-forms of the cytokines interleukin
(IL)-1β and IL-18 to their active and secreted forms of
which IL-1β is of particular importance as an upstream
mediator in the inflammatory cytokine cascade (15). Compelling
evidence suggests a significant role of NLRP3 inflammasome
in the initiation and progression of metaflammation (i.e.,
metabolically-induced inflammation) and related diseases, such
as obesity, T2DM, NAFLD, and atherosclerosis (16–18). In
addition, we and others have recently demonstrated that NLRP3
inflammasome is functional in the heart with the potential to
regulate cardiac function and cell death (19). Based on these
previous studies, we hypothesized that the NLRP3 inflammasome
plays a role in the development of cardiac dysfunction and
remodeling during diet-induced obesity. The present study was
designed to explore this hypothesis by examining Nlrp3 and
ASC (Pycard) deficient mice in a model of obesity induced
cardiac remodeling.
METHODS
Mice
C57BL/6J mice were purchased from The Jackson Laboratory
(Bar Harbor, ME, USA). All knockout mice were back-bred onto
the C57BL/6 strain. Nlrp3−/− and Asc−/− (Pycard−/−) mice
were generated by Millenium Pharmaceuticals (Cambridge, MA,
USA), back-bred at least seven (Nlrp3−/−) or nine (Asc−/−/
Pycard−/−) generations before being used (20, 21). Mice were
housed in an air-conditioned, temperature-regulated room with
a 12/12 h daylight/night cycle with free access to water and food.
The diet and genetic background are major determinants of gut
microbial composition which again could influence metabolic
and inflammatory diseases. To minimize the effects of other
factors than genetics in our study, including effects on gut
microbiota, the mice were co-housed throughout the study. The
separate mouse strains were littermates, bred from the same
parents, raised in the same cage until weaning where 4–6 mice
of the same strain where co-housed in the same open cages
(Eurostandard type III), and all cages were placed in the same
room in a randomized manner. Obesity was induced by feeding
mice a HFD (D12492), composed of 60% fat, 20% protein, and
20% carbohydrate (Research Diets, New Brunswick, NJ, USA) for
52 weeks. Control mice were fed a low fat standardized control
diet, containing 10% fat, 20% protein and 70% carbohydrate
(D12450B, ResearchDiets). Body weight was regularlymonitored
weekly. Food intake was determined at 21 weeks by weighing the
food and correcting for the amount not eaten, including spillage.
The experimental animal protocol (FOTS id 4641) was approved
by the Norwegian Animal Research Committee and conforms to
the Guide for the Care and Use of Laboratory Animals published
by the US National Institutes of Health (NIH Publication, 8th
Edition, 2011).
Echocardiography
Echocardiographic examination was performed with the VEVO
2100 system (VisualSonics, Toronto, Canada). Mice were
lightly anesthetized with a mixture of 98.25% O2 and 1.75%
isoflurane maintained by mask ventilation, and were placed
on a heated examination table to maintain body temperature.
Standard echocardiography examination, including long and
short axis images of the LV and atrium, and doppler recordings,
were performed (22). Recorded data were analyzed offline
using the Vevo 2100 1.1.0 software (VisualSonics). Relative
LV wall thickness was calculated with the formula: (IVSd
+ LVPWd)/LVIDd.
Magnetic Resonance Imaging
Magnetic Resonance Imaging (MRI) experiments were
performed by using a 9.4T preclinical MR system (Agilent
Technologies, Inc., CA, USA). Two different gradients and RF
coil set-ups have been employed because of the mice changing
size during the study period. The images were acquired with
either a 100 gauss/cm, 60mm ID gradient and a quadrature
volume RF coils (35mm ID, Rapid Biomedical, DE) or a 60
gauss/cm, 72mm ID gradient and an active-decoupled phase
array surface coil (Neos Biotec, Spain) plus quadrature volume
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RF coils (72mm ID, Rapid Biomedical) combination. Anesthesia
was induced with a mixture of O2 and 4% isoflurane, and
maintained with 1.5–2.0% isoflurane in freely breathing animals.
Animal temperature was maintained around 37◦C by heated
air. Cardiac and respiratory gated cine-MRI was acquired in
the true short-axis orientation. The key parameters were 1mm
slice thickness; TE/TR 2.2/4.6ms; 2 averages; field of view 25.6
× 25.6mm; matrix size 128 × 128. One mid-ventricular slice
and one four chamber long axis slice were acquired using a
nine-point velocity-encoded black-blood gradient echo cine
sequence as previously described (23). Imaging parameters
were: TE = 2.4ms; TR = 3.2ms; field-of-view = 30 × 30mm
or 40 × 40mm; acquisition matrix 96 × 96 and zero filled to
128 × 128; slice thickness 1mm; venc = 10 cm/s, averages = 2
(using rotating field-of-view). Data were analyzed as previously
described (24).
Blood and Tissue Sampling
Mice were fasted for 4 h and put in deep anesthesia with amixture
of 4–5% isoflurane and O2. Arterial blood was collected (by a
small incision of the carotid artery) into tubes containing 50 µl
of 0.5M EDTA. Plasma was prepared by centrifugation at 500
× g for 20min and 4◦C, snap-frozen in liquid N2 and stored at
−80◦C. The heart was extirpated and separated into LV and RV,
together with lungs and liver, rinsed in saline solution, blotted dry
and weighed. A standardized 2mm slice was taken from the LV
using a mouse heart slicer matrix (Zivic instruments, Pittsburgh,
PA, USA). The heart slice and the left lateral lobe of the liver were
fixated in 4% formalin and embedded in paraffin. Remaining
tissue was snap-frozen in liquid N2 and stored at−80
◦C.
Analysis of Glucose, Lipids, and
Inflammatory Cytokines
Plasma insulin was determined by Mouse Ultrasensitive Insulin
ELISA (ALPCO, Salem, NH, USA), plasma leptin by Mouse
Leptin ELISA (ALPCO), plasma glucose by Mouse Glucose
Colorimetric Assay kit (Cayman, Ann Arbor, MI, USA),
triglycerides by LabAssay Triglyceride (WakoPure Chemical
Industries, Richmond, VA, USA), and cholesterol by Cholesterol
E (Wako Diagnostics, Richmond, VA, USA). Homeostasis model
assessment—insulin resistance (HOMA-IR) was calculated
using the following formula: HOMA-IR = [I0(mU/L) ×
G0(mg/dl)]/405 (25). Plasma levels of interleukin IL-18 and TNF
were measured by using multiplex magnetic bead assay (Bio-Rad
Laboratories, Berkeley, CA, USA) following the manufacturer’s
instructions. LV triglyceride levels were measured using
LabAssay Triglyceride kit (WakoPure Chemical Industries).
Liver Histology and Lipids
To examine liver histology, livers were fixed in formalin
and embedded in paraffin and then cut into 5µm sections.
Sections were deparaffinized and stained with hematoxylin
(Vector Laboratories, Burlingame, CA, USA) and eosin (Histolab
Products AB, Gothenburg, Sweden). Images were captured by
use of a Nikon DS Fi1 camera and a Nikon Eclipse E400
microscope (Nikon Instruments, Melville, NY, USA). Liver lipids
were extracted from frozen samples according to Bligh and Dyer
(26), evaporated under nitrogen, and re-dissolved in isopropanol
before analysis. Lipids from liver were measured enzymatically
on a Hitachi 917 system (Roche Diagnostics GmbH, Mannheim,
Germany) using the TAG kit (Triglycerides GPO-PAP) and
cholesterol kit (CHOD-PAP) from Roche Diagnostics.
Cardiac Histology and
Immunohistochemistry
Four micron transverse sections of formalin-fixed, paraffin-
embedded mouse hearts were deparaffinized in xylene,
rehydrated in alcohol series and immersed in distilled water,
followed by high-temperature antigen retrieval in citrate
buffer (pH 6) and blocked with 0.5% bovine serum albumin
(Sigma-Aldrich, St. Louis, MO, USA). Slides were stained
with primary antibody against Mac-2 (1:750, Cedarlane,
Burlington, Canada) for 1 h at room temperature. After washing,
slides were incubated for 30min with peroxidase-conjugated
secondary antibody (Impress-Vector, Vector Laboratories),
rinsed and developed with chromogen for immunoperoxidase
staining (DAB Plus, Vector Laboratories). The sections were
counterstained with hematoxylin. Omission of the primary
antibody was used as negative control. The stained sections were
scanned (AxioScan Z1, Carl Zeiss, Oberkochen, Germany), and
the amount of positive DAB-staining was quantitatively assessed
using z9.uio.no, an in-house analysis application devised for
whole slide images, by estimating cross sectional coverage of
antibody expression within the tissue relative to the total area of
the cross section of the tissue.
To measure cardiomyocyte (CM) cross-sectional area, LV
sections were deparaffinized and rehydrated as described above
and boiled at 98◦C in citrate buffer pH 6, followed by 20min
cooling at room temperature (RT) before overnight incubation at
(4◦C) with Alexa-488 conjugated wheat germ agglutinin (WGA;
Thermo Fisher Scientific, Waltham, MA, USA). Sections were
rinsed in PBS and coverslipped with a water-soluble antifading
mounting medium (Thermo Fisher Scientific). Areas showing
CM cross sections were photographed with Nikon Eclipse E400
fluorescence microscope and CM area was quantified by an in
house made macro for ImageJ (27). All histological analyses were
performed blinded of genotype and treatment.
Collagen Staining
For collagen staining, sections were deparaffinized and
rehydrated as described above. Sections were thereafter
incubated for 60min in Sirius Red Solution (Histolab Products)
followed by 2 × rinsing in acidified water containing 5%
acetic acid. After two quick dips in 100% EtOH, the sections
were incubated in xylene and mounted with Eukitt R© (Sigma-
Aldrich). The stained sections were scanned and analyzed as
described for Mac-2, but detecting red chromogen instead of
DAB-positive staining.
Quantification of Gene Expression
Total RNA from mouse LV was extracted using TRIzol
(Invitrogen, San Diego, CA, USA), DNase treated, cleaned
up using RNeasy Mini Columns (Qiagen, Hilden, Germany),
and stored at −80◦C. cDNA was synthesized using High
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Capacity cDNA Reverse Transcription Kit (Thermo Fisher
Scientific). Quantification of gene expression was performed
in duplicate by quantitative real-time PCR, using Power
Sybr Green Master Mix (Applied Biosystems, Foster By, CA,
USA). Target gene expression was quantified using the relative
standard curve method, using a standard curve generated
with serial dilution of a pool of aliquots of sample cDNA,
and subsequently normalized to glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) gene expression. Primers, designed to
span exon-exon boundaries to avoid amplification of genomic
DNA, were used. The sequences of the specific PCR-primers are
listed in Supplementary Table S1.
Assessment of Peripheral Insulin
Sensitivity
WTandNlrp3−/−mice onHFD or control diet for 52 weeks were
fasted for 4 h and received an i.p. injection of insulin (2 IU/kg
of Novolin GE, Novo Nordisk, Bagsværd, Denmark). The mice
were sacrificed 10min after insulin administration, LV and liver
samples were isolated and snap-frozen in liquid N2, and protein
homogenates were prepared in T-PER Tissue Protein Extraction
Reagent (Thermo Fisher Scientific) supplemented with protease
and phosphate inhibitors (Complete Protease Inhibitor
Cocktail, Roche Diagnostics), cleared by centrifugation, and
concentrations were measured using a Pierce BCA Protein Assay
(Thermo Fisher Scientific). Protein homogenates were separated
under denaturing conditions on 10% SDS-polyacrylamide gels
(Mini-PROTEAN TGX Precast gels, Bio-Rad, Hercules, CA,
USA) and electro-blotted on to PVDF membranes (Thermo
Fisher Scientific). The membranes were blocked in Superblock
T20 (Thermo Fisher Scientific), and incubated with antibodies
against phospho-Akt Ser473 (1:1,000 dilution; Cat# 9271, Cell
Signaling Technology, Danvers, HA, USA), Akt (1:1,000; Cat#
9272, Cell Signaling Technology), and GAPDH (0.05µg/ml;
Cat# G8795, Sigma-Aldrich) which was used as a normalization
control for the proteins of interest. Thereafter, the blots were
incubated with a horseradish peroxidase-conjugated anti-rabbit
or anti-mouse antibody (Cell Signaling Technology). Protein
expression was detected by chemiluminescence (SuperSignal
Dura; Thermo Fisher Scientific) and the Fujifilm LAS-3000
Imaging system. Densitometric quantification was performed
using ImageJ.
Statistical Analysis
GraphPad Prism 7.0 software was used for data analysis
(GraphPad Software, CA, USA). Statistical analyses were
performed using two-way ANOVA. Student t-tests were
performed where two-way ANOVA was significant. p-value
below 0.05 was considered as statistical significance. Data are
shown as mean± standard error of the mean (SEM).
RESULTS
NLRP3 Inflammasome Does Not Affect
Obesity-Induced LV Hypertrophy
Exposure to a HFD for 52 weeks induced profound obesity as
compared to mice fed a control diet in all three genotypes (i.e.,
WT, Nlrp3−/−, and Asc−/− [Pycard−/−] mice) (Figure 1A).
A significant separation of body weight between mice on
HFD and control diet was observed from week 9, determining
the initial moment of obesity. Notably, although all mouse
genotypes showed increased weight during HFD, WT mice
gained significantly more weight than the inflammasome
deficient mice (Figure 1A). In contrast, no differences
in weight gain were seen between the three genotypes
during control diet (Figure 1A). Importantly, there were
no significant differences in food intake comparing the
different mouse genotypes (Supplementary Figure S1).
As expected, HFD-induced obesity was associated with
significant cardiac hypertrophy in WT mice, as indicated by an
increased LV mass normalized to tibia length (Figure 1B) and
increased CM cross-sectional area (Figures 1C,D). However,
whereas NLRP3 and ASC deficiency affected body weight
during HFD, it did not affect obesity-induced hypertrophic
response (Figures 1B–D).
NLRP3 and ASC Deficiency Have a
Beneficial Effect on Obesity-Induced LV
Remodeling and Dysfunction
Cardiac structure was monitored by echocardiography. As
displayed in Figure 2A, HFD induced a significant increase in
LV end-diastolic internal diameter (LVIDd) inWT andNlrp3−/−
mice, with a non-significant trend in Asc−/− (Pycard−/−) mice
(p = 0.22). WT mice on HFD also had markedly increased
LV end-diastolic posterior wall (LVPWd) thicknesses and end-
diastolic intraventricular septum (IVSd) (Figures 2B,C), but,
notably, this was not observed in Nlrp3−/− and Asc−/−
(Pycard−/−) mice. To further assess geometrical changes in
the LV, we calculated relative wall thickness (RWT). This
revealed a clear pattern of concentric remodeling in obese
WT mice (RWT > 0.48), but not in Nlrp3−/− and Asc−/−
(Pycard−/−) mice, which were protected against these obesity-
induced alterations (Figure 2D).
Cardiac MRI analysis allowed us to more accurately assess
cardiac mechanics and function and showed that obesity
induced a significant reduction in LV systolic function in
WT mice, but not in Nlrp3−/− and Asc−/− (Pycard−/−),
as determined by longitudinal strain (Figure 2E). Moreover,
whereas obeseWTmice displayed impaired LV diastolic function
as evident by a markedly reduced mitral annulus velocity
during early diastole (e′), this was not seen in NLRP3 and
ASC (Pycard) deficient mice (Figure 2F). Notably, on control
diet both Nlrp3−/− and Asc−/−(Pycard−/−) mice had reduced
e′ compared to WT, but obesity did not affect e′ in these
mice. There were no statistical differences in gene expression of
atrial natriuretic peptide (ANP) between the different groups,
indicating that the fetal gene programme was not activated by
HFD (Supplementary Figure S2).
Taken together, our results so far show that NLRP3
and ASC deficiency during obesity does not affect the
hypertrophic response but prevents obesity-induced LV
concentric remodeling and early signs of systolic and
diastolic dysfunction.
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FIGURE 1 | NLRP3 inflammasome does not affect obesity-induced LV hypertrophy. WT, Nlrp3−/−, and Asc−/− (Pycard−/−) male mice were exposed to high fat diet
(HFD; 60 cal% fat) or control diet for 52 weeks. (A) Comparison of bodyweight gain in mice on control or HFD during the 52 weeks [WT: Control, n = 12; HFD, n = 12,
Nlrp3−/−: Control, n = 11; HFD, n = 12, and Asc−/− (Pycard−/−): Control, n = 10; HFD, n = 12]. (B) Left ventricle (LV) weight normalized to tibia length weeks [WT:
Control, n = 11; HFD, n = 11, Nlrp3−/−: Control, n = 8; HFD, n = 8, and Asc−/− (Pycard−/−): Control, n = 10; HFD, n = 6]. (C) Representative images of wheat
germ agglutinin (WGA) stained LV sections [WT: Control, n = 8; HFD, n = 9, Nlrp3−/−: Control, n = 7; HFD, n = 7, and Asc−/− (Pycard−/−): Control, n = 8; HFD,
n = 5). Scale bar: 100µm. (D) Quantification of cardiomyocyte cross-sectional surface area. Data are means ± SEM. *P < 0.05, **P < 0.01 vs. control diet as
determined by two-way ANOVA and Tukey’s multiple comparisons test. #P < 0.05 vs. NLRP3-HFD and ASC-HFD as determined by repeated measures two-way
ANOVA and Tukey’s multiple comparisons test.
NLRP3 and ASC Deficiency Protects
Against Obesity-Induced Metabolic
Dysfunction and Inflammation
Obesity-induced changes in the myocardium could be secondary
to systemic changes. We, therefore, next examined the
influence of NLRP3 inflammasome on systemic, metabolic
and inflammatory changes following 52 weeks on HFD. Plasma
glucose and in particular insulin levels and insulin resistance,
as assessed by HOMA-IR, were all elevated in obese WT mice
(Figures 3A–C), with no significant changes in Nlrp3−/− and
Asc−/− (Pycard−/−) mice. This suggests that the absence of
inflammasome components led to improved maintenance of
glucose homeostasis and increased insulin sensitivity during
HFD. Similarly, Nlrp3−/− and Asc−/− (Pycard−/−) mice were
protected against HFD-induced dyslipidaemia, while WT mice
demonstrated significantly elevated triglycerides (TG) and
cholesterol plasma levels in response to HFD (Figures 3D,E).
Excessive leptin production is associated with high BMI and
insulin resistance in T2DM (28), and as expected, HFD-
fed WT mice exhibited a marked increase in plasma leptin
compared with mice on control diet (Figure 3F). This increase
in leptin levels during HFD was significantly attenuated in
NLRP3 and ASC (Pycard) deficient mice (Figure 3F). Finally,
metabolic disturbances during obesity seems to interact with
low-grade inflammation, and as shown in Figure 3G, IL-18 levels
were significantly elevated in obese WT mice, but remained
unchanged in HFD fed Nlrp3−/− and Asc−/− (Pycard−/−) mice
(Figure 3G), using an assay which detects only the mature form
of IL-18. Furthermore, HFD increased plasma levels of TNF,
which was alleviated by NLRP3 and ASC deficiency (Figure 3H).
Thus, it seems that NLRP3 and ASC deficiency protects mice
against HFD-induced metabolic dysregulation, increased leptin
levels and systemic inflammation. Plasma levels of IL-1β were
under the detection limit in all mice (data not shown), using a
highly sensitive method (Bio-Plex Pro, Bio-Rad).
Absence of NLRP3 Inflammasome
Components Suppresses Obesity-Induced
Hepatic Steatosis
Liver is a target organ for metabolic changes during obesity.
We, therefore, performed a thorough pathological examination
of the liver with respect to mouse genotypes and the diets.
As illustrated in Figure 4A, consumption of a HFD resulted
in an abnormal appearance with atypical yellowish coloration
of the livers from WT mice with severe steatosis and lipid
droplet accumulation, while livers from Nlrp3−/− and Asc−/−
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FIGURE 2 | Beneficial effect of NLRP3 and ASC deficiency on obesity-induced LV concentric remodeling and dysfunction. WT, Nlrp3−/−, and Asc−/− (Pycard−/−)
male mice were exposed to a high fat diet (HFD; 60 cal% fat) or a control diet for 52 weeks. Cardiac structure and function was assessed by echocardiography. WT:
Control, n = 6; HFD, n = 10, Nlrp3−/−: Control, n = 6; HFD, n = 7, and Asc−/− (Pycard−/−): Control, n = 6; HFD, n = 7, and cardiac magnetic resonance imaging
[MRI; WT: Control, n = 6; HFD, n = 6, Nlrp3−/−: Control, n = 6; HFD, n = 6, and Asc−/− (Pycard−/−): Control, n = 6; HFD, n = 6]. (A) Left ventricular internal
diameter at end diastole (LVIDd), (B) LV posterior wall thickness at end diastole (LVPWd), (C) interventricular septum thickness at end diastole (IVSd), (D) LV relative
wall thickness (RWT), (E) longitudinal strain (MRI), and (F) early diastolic mitral annular velocity (e′ peak; MRI). Data are means ± SEM. *P < 0.05, **P < 0.01,
***P < 0.001 vs. control diet. #P < 0.05 vs. WT HFD.
(Pycard−/−) mice retained dark red coloration without steatosis.
There was no accumulation of lipid droplets in livers from the
mice on a control diet in either of the genotypes as evaluated by
hematoxylin and eosin staining (Figure 4A). Liver weights were
markedly elevated in WT mice compared with Nlrp3−/− and
Asc−/− (Pycard−/−) mice during HFD, but not during control
diet (Figure 4B). HFD-induced liver steatosis in WT mice
was also verified biochemically with markedly elevated hepatic
levels of cholesterol and TG (Figures 4C,D), and importantly,
Nlrp3−/− and Asc−/− (Pycard−/−) livers showed significantly
reduced levels of these lipid components in response to HFD
feeding compared with WT mice (Figures 4A–D). Thus, in line
with our findings that NLRP3 and ASC (Pycard) deficient mice
were protected against obesity-induced metabolic dysfunction
(Figure 3), these mice were also able to suppress development of
hepatic steatosis during HFD.
Obesity-Induced LV Remodeling Is Not
Associated With Cardiac Fibrosis and
Inflammation
Previous studies have suggested that cardiac fibrosis and
inflammation are potential contributors to obesity-induced
changes in cardiac structure and function (29). However, as
indicated in Figure 5A and quantified in Figure 5B, there
was no cardiac fibrosis development in none of the obese
mouse genotypes. Moreover, although we found increased
gene expression of collagen I mRNA in obese WT mice,
in general the differences were modest across the different
genotypes and without any differences in collagen III mRNA
levels (Figures 5C,D). Cardiac inflammation was evaluated
by staining for Mac-2 positive macrophages (Figure 6A). We
did observe a significant increase in Mac-2 positive staining
in WT mice on HFD compared to WT mice on control
diet (Figure 6B), with the same tendency in Nlrp3−/− and
Asc−/− (Pycard−/−) mice. The absolute number of Mac-2
macrophages was however low in all genotypes. Moreover,
cardiac gene expression of IL-1β, IL-18, and TNF was not
statistically different between mice on control diet and HFD
and between the different genotypes (Figures 6C–E). We also
evaluated cardiac NLRP3 gene expression, and in line with
expression of inflammatory cytokines, there was no increase
in NLRP3 mRNA in WT and Asc−/− (Pycard−/−) mice on
HFD (Figure 6F). Finally, we were not able to detect the
mature IL-1β protein by western blot technique within the
myocardium in either of the genotypes (data not shown).
These results may suggest that HFD-induced myocardial
remodeling was not related to local cardiac inflammation or
fibrosis, but rather systemic effects, i.e., inflammation and
metabolic changes.
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FIGURE 3 | NLRP3 and ASC deficiency protects mice against obesity-induced metabolic dysregulation and inflammation. WT, Nlrp3−/−, and Asc−/− (Pycard−/−)
male mice were exposed to a high fat diet (HFD; 60 cal% fat) or a control diet for 52 weeks and plasma was collected. Plasma (A) glucose, (B) insulin, (C) HOMA-IR
[homeostatic model assessment of insulin resistance calculated from measured glucose and insulin levels], (D) triglycerides, (E) cholesterol, (F) leptin, (G) interleukin
(IL)-18, and (H) tumor necrosis factor (TNF). WT: Control, n = 8; HFD, n = 8, Nlrp3−/−: Control, n = 8; HFD, n = 7, and Asc−/−: Control, n = 7; HFD, n = 7. Data are
means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. control diet; #P<0.05 vs. WT-HFD as determined by two-way ANOVA and Tukey’s multiple comparisons test.
Cardiac Insulin Sensitivity Is Preserved in
Obese NLRP3 Deficient Mice
As in the livers (Figure 4), heart homogenates from WT mice
showed a significant HFD-induced elevation of TG content,
which was not seen in the Nlrp3−/− and Asc−/− (Pycard−/−)
hearts (Figure 7A). It is increasingly accepted that impaired
insulin signaling could affect metabolic changes in various
tissues during obesity (30). To determine whether downstream
insulin signaling was altered in the hearts and livers of obese
WT and Nlrp3−/− mice, we examined the acute effect of a
subcutaneous injection of insulin (2 IU/kg) on phosphorylation
at Ser473 of Akt, a major target of insulin receptor signaling.
The serine-threonine kinase Akt is activated by several ligand-
receptor systems previously shown to be cardioprotective (31).
While obese WT mice showed a marked reduction in Akt
phosphorylation upon insulin treatment in both cardiac and
hepatic tissue,Nlrp3−/−mice were protected against this obesity-
induced effect (Figures 7B,C).
DISCUSSION
Obesity and metabolic disease-related cardiac remodeling and
HF are a growing worldwide concern (4, 5). The NLRP3
inflammasome may represent a molecular link between over
nutrition, metabolic stress, inflammation and development of
metabolic and cardiovascular diseases. Herein, we examined the
effect of long-term HFD consumption on obesity associated
cardiac remodeling in NLRP3 and ASC (Pycard) deficient mice.
We found that the cardiac hypertrophic response to obesity
was independent of the NLRP3 inflammasome, while deficiency
of NLRP3 and ASC blunted the concentric form of cardiac
remodeling and the impairment of diastolic function seen in
Frontiers in Immunology | www.frontiersin.org 7 July 2019 | Volume 10 | Article 1621
Sokolova et al. NLRP3 in Obesity-Induced Cardiac Remodeling
FIGURE 4 | Obesity-induced hepatic steatosis is suppressed by NLRP3 and ASC deficiency. WT, Nlrp3−/−, and Asc−/− (Pycard−/−) male mice were exposed to
high fat diet (HFD; 60 cal% fat) or a control diet for 52 weeks and liver was extirpated. (A) Representative images of livers and hematoxylin and eosin staining from
mice on HFD and Control diet. Scale bar: 100µm. (B) Liver weights related to tibia length (TL). Hepatic levels of (C) cholesterol and (D) triglycerides. WT: Control, n =
10; HFD, n = 10, Nlrp3−/−: Control, n = 7; HFD, n = 7, and Asc−/−(Pycard−/−): Control, n = 9; HFD, n = 5. Data are shown as mean ± SEM. **P < 0.01,
***P < 0.001 vs. control diet; #P < 0.05, ##P < 0.01, ###P < 0.001 vs. WT-HFD as determined by two-way ANOVA and Tukey’s multiple comparisons test.
obeseWTmice. Whereas, NLRP3 and ASC deficiency attenuated
systemic inflammation and metabolic disturbances in HFD fed
mice; long-term HFD did not induce significant cardiac fibrosis
or inflammation, suggesting that the beneficial effects of NLRP3
inflammasome deficiency on myocardial remodeling at least
partly reflect systemicmechanisms. However, in both hepatic and
cardiac tissue, NLRP3 inflammasome deficiency counteracted
lipid accumulation and the impaired insulin signaling in WT
mice on HFD. The latter mechanisms could be an important
mediator of the beneficial effect of NLRP3 deficiency on HFD
induced myocardial remodeling, linking systemic and local
effects within the myocardium.
Many different models have been used to address mechanisms
for how obesity and metabolic disease causes cardiac remodeling
and HF development, including leptin or leptin receptor
deficient mice and mice with pharmacologically induced (e.g.,
streptozotocin) diabetes (32). In this study we used a model of
diet-induced obesity (60% calories from fat), as it recapitulates
many of the obesity-associated conditions in humans, such
as adipose tissue remodeling, insulin resistance and hepatic
steatosis. The reported cardiac phenotype of mice fed a HFD over
an extended period of time varies in severity (33). However, the
phenotype of our obese mice is similar to some previous studies,
i.e., not overt HF, but more resembling the early alterations
associated with development of diabetic cardiomyopathy (34,
35). Thus, while others have observed HF developing after
15 weeks using the same protocol (36), we found consistent
cardiac hypertrophy and a concentric form of LV remodeling
without overt HF in the WT mice. Our data show that although
NLRP3 and ASC (Pycard) deficient mice gained significantly
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FIGURE 5 | Obesity-induced LV remodeling is not associated with cardiac fibrosis. WT, Nlrp3−/−, and Asc−/− (Pycard−/−) male mice were exposed to high fat diet
(HFD; 60 cal% fat) or control diet for 52 weeks and cardiac fibrosis was evaluated. (A) Representative images of picrosirius red stained left ventricle (LV) from a WT
mouse on control diet and HFD. Scale bar: 500µm. (B) Quantification of picrosirius red positive areas in LV. LV expression of (C) collagen I mRNA and (D) collagen III
mRNA. WT: Control, n = 10; HFD, n = 10, Nlrp3−/−: Control, n = 7; HFD, n = 7, and Asc−/− (Pycard−/−): Control, n = 7; HFD, n = 7. Data are shown as mean ±
SEM. **P < 0.01 vs. control diet; #P < 0.05 vs. WT-HFD as determined by two-way ANOVA and Tukey’s multiple comparisons test.
less weight after 1 year on a HFD, all three genotypes did
develop obesity, which was associated with cardiac hypertrophy,
with similar heart weights and cardiomyocyte cross-sectional
areas in the different mouse strains. However, NLRP3 and
ASC (Pycard) deficiency appears to be preventive against LV
concentric remodeling with potentially beneficial effects on
cardiac geometry and diastolic dysfunction, the latter may
be of particular relevance in relation to metabolic induced
cardiomyopathy (4).
Inflammation is suggested to play a pathogenic role in
development of myocardial dysfunction, including diabetic
cardiomyopathy and HF with preserved ejection fraction
(HFpEF). Others and we have previously implicated the NLRP3
inflammasome as a pathogenic mediator acting locally in the
heart in ischemia reperfusion injury (19, 37, 38). Somewhat
surprisingly, we did not find increased cardiac inflammation or
cardiac fibrosis after 52 weeks of HFD in the present study.
However, this is in fact in line with some previous studies
(34, 35), illustrating the contrast between our model and those
of e.g., leptin receptor deficiency (i.e., db/db mice) and type 1
diabetes (e.g., streptozotocin treatment) (33). In a rat model of
streptozotocin and HFD-induced diabetic cardiomyopathy with
severe cardiac inflammation and fibrosis, Luo et al. previously
reported beneficial effects of NLRP3 gene silencing (39). More
recently, and in contrast to our findings, Pavillard et al. showed
reduced cardiac hypertrophy in NLRP3 deficient mice and
NLRP3 inhibition with MCC950 during HFD for 15 weeks (40).
This discrepancy might be explained by the different durations
of the experiments, 15 and 52 weeks, respectively. Also, they did
not include in vivo examination of cardiac structure and function.
Nonetheless, in our opinion, long-term exposure to HFD is a
relevant model for examining the effects of an unhealthy diet and
obesity on the myocardium, and will more accurately reflect the
situation in patients withmoderate obesity, T2DM, liver steatosis,
hyperlipidemia and insulin resistance than the models of leptin
receptor deficiency (i.e., db/db mice) and type 1 diabetes (e.g.,
streptozotocin treatment).
NLRP3 inflammasome is considered to have a critical role
in sensing obesity-associated metabolic stress and mediating
the associated inflammatory response and insulin resistance
development (14, 41). This was confirmed in our study with a
marked reduction in systemic, hepatic and also cardiac measures
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FIGURE 6 | Obesity-induced LV remodeling is not associated with cardiac inflammation. WT, Nlrp3−/−, and Asc−/− (Pycard−/−) male mice were exposed to high fat
diet (HFD; 60 cal% fat) or control diet for 52 weeks and cardiac inflammation was evaluated. (A) Representative images of Mac-2 positive macrophages (arrows) in left
ventricle (LV) from a WT mouse on control diet and HFD. Scale bar: 100µm. (B) Quantification of Mac-2 positive areas in LV. LV gene expression, of (C) interleukin
(IL)-1β mRNA, (D) IL-18, (E) tumor necrosis factor (TNF), and (F) NLRP3, presented relative to levels of GAPDH mRNA. WT: Control, n = 10; HFD, n = 10, Nlrp3−/−:
Control, n = 7; HFD, n = 7, and Asc−/− (Pycard−/−): Control, n = 7; HFD, n = 7. Data are shown as mean ± SEM. *P < 0.05 vs. control diet; #P < 0.05 vs.
WT-HFD as determined by two-way ANOVA and Tukey’s multiple comparisons test.
of insulin resistance. It is increasingly accepted that impaired
insulin signaling could affect metabolic changes in various
tissues during obesity (30). Moreover, the serine-threonine
kinase Akt, a major target of insulin receptor signaling, has
previously shown to be cardioprotective. This is in line with our
results showing that while obese WT mice exhibited a marked
reduction in Akt phosphorylation upon insulin treatment in
both cardiac and hepatic tissue, this was not seen in NLRP3−/−
mice. The latter mechanism could be an important mediator
of the beneficial effect of NLRP3 deficiency on HFD induced
myocardial remodeling, linking systemic and local effects within
the myocardium.
Moreover, plasma levels of mature IL-18, activated by the
NLRP3 inflammasome, and TNF, a cytokine that could be
activated down-stream to NLRP3 activation, were increased
with obesity and markedly reduced in inflammasome deficient
mice. Thus, even though there was no cardiac inflammation,
there was an NLRP3-dependent systemic inflammatory response
to obesity. Also, NLRP3 inflammasome deficiency reduced
triglyceride levels both in the liver and within the heart. Based
on our own and previous findings, it is tempting to term the
Nlrp3−/− and Asc−/− (Pycard−/−) mice as models of cardiac
response in metabolically healthy obesity (42). In extension of
this, we hypothesize that the hypertrophic response we observe is
related to the obesity per se.However, the concentric remodeling,
a hallmark feature of diabetic cardiomyopathy and HFpEF was
not observed in the inflammasome deficient mice suggesting
that these features may be NLRP3 inflammasome-dependent.
The lack of local cardiac inflammation and fibrosis in our
results, suggests that the cardiac remodeling and dysfunction
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FIGURE 7 | Cardiac insulin sensitivity is preserved in obese NLRP3 deficient mice. WT, and Nlrp3−/− male mice were exposed to high fat diet (HFD; 60 cal% fat) or
control diet for 52 weeks. (A) Left ventricle concentration of triglycerides [WT: Control, n = 10; HFD, n = 10, Nlrp3−/−: Control, n = 7; HFD, n = 7, and, Asc−/−
(Pycard−/−): Control, n = 7; HFD, n = 7]. WT and Nlrp3−/− mice on control diet or HFD for 52 weeks were fasted for 4 h and received an i.p. injection of insulin (2
IU/kg). Mice were euthanized and after 10min heart and liver were extirpated. Ratio of phosphorylated (Ser473) Akt to total Akt in mice on control diet or HFD in (B)
left ventricle and (C) liver (WT: Control, n = 6; HFD, n = 4, Nlrp3−/−: Control, n = 4; HFD, n = 4) were determined by immunoblot analysis. Data are normalized to
corresponding GAPDH. Data are shown as mean ± SEM. *P < 0.05, **P < 0.01 vs. control diet; #P < 0.05 vs. WT-HFD as determined by two-way ANOVA and
Tukey’s multiple comparisons test.
in obese WT mice is more likely mediated by external factors,
such as systemic inflammatory and metabolic responses, rather
than intrinsic processes in the heart, and these systemic
responses are attenuated in NLRP3 inflammasome deficient
mice. It is, therefore, tempting to hypothesize that NLRP3
inflammasome may link low-grade systemic inflammation to
maladaptive myocardial remodeling and impaired diastolic
function with insulin resistance as an important mediator within
the myocardium. Notably, this model is in agreement with
the novel HFpEF paradigm postulated by Paulus and Tschope,
which suggest that a systemic inflammatory state induced by
comorbidities, such as obesity and diabetes mellitus, triggers
concentric cardiac remodeling and LV dysfunction in HFpEF
(6). Our findings may suggest that NLRP3 inflammasome could
be an important mediator in this process. Whereas, we found
significantly higher levels of the mature IL-18 protein in WT
as compared to Nlrp3−/− and Asc−/− (Pycard−/−) mice, none
of the genotypes showed detectable levels of IL-1β in plasma
(multiplex) and myocardium (western blot). The inability to
measure IL-1β does, however, not mean that this NLRP3
inflammasome product is of less importance than IL-18. It could
rather reflect technical problems with measuring this cytokine
in mice models that has also previously been recognized (43).
Although being a very potent cytokine, IL-1β is usually released
in small amounts and has a very short plasma half-life (44).
The present study has some limitations as we did not use co-
housed littermate controls all through the study. To minimize
the effects of other factors than genetics, including effects on
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gut microbiota, the separate mouse strains were littermates; bred
from the same parents, raised in the same cage until weaning
where 4–6 mice of the same strain where co-housed in the
same open cages. Gut microbiota has been recently established
to have a contributory role in the development of cardio-
metabolic disorders, such as atherosclerosis, obesity, and T2DM
(45), and the impact of this “new organ.” should be investigated
in forthcoming studies. Moreover, based on our experimental
approach, we cannot conclude if the cardiac phenotype in
Nlrp3−/− and Asc−/− (Pycard−/−) mice is secondary to weight
gain or caused by direct effect of NLRP3 inflammasome on
myocardial function.
Collectively, our data suggests that obesity drives cardiac
hypertrophy per se, while systemic inflammation and metabolic
dysfunction promotes adverse effects on cardiac remodeling
and function, and these systemic effects were attenuated
in Nlrp3−/− and Asc−/− (Pycard−/−) mice. Although our
data may suggest a role for improved insulin-mediated Akt
phosphorylation in Nlrp3−/− and Asc−/− (Pycard−/−) mice,
further studies are needed to elucidate themolecular mechanisms
for the role of NLRP3 activation during HFD, including the
effects on myocardial remodeling. Further studies should also
address NLRP3 inflammasome as a target for therapy in both
experimental and clinical metabolic induced cardiac remodeling
including HFpEF.
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